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Abstract
Penetrances of BRCA1 and BRCA2 mutations have been derived from retrospective studies, implying the possibility
of ascertainment biases to influence the results.
We have followed women at risk for breast and/or ovarian cancer for two decades, and report the prospectively
observed age-related annual incidence rates to contract breast or ovarian cancer for women with deleterious
BRCA1 or BRCA2 mutations based on 4830 observation years. Patients were grouped according to mutation, age
and having/not having had previous cancer.
In women not having had previous cancer and aged 40-59 years, the annual incidence rate to contract breast or
ovarian cancer in those having the most frequent BRCA1 founder mutations was 4.0%, for women in this age
group and with less frequent BRCA1 mutations annual incidence rate was 5.9%, and for women with BRCA2 muta-
tions 3.5%.
The observed figures may be used for genetic counseling of healthy mutation carriers in the respective age
groups. The results may indicate that less frequent BRCA1 mutations have higher penetrances than BRCA1 founder
mutations.
Introduction
Mutations in the two genes BRCA1 and BRCA2 may
cause breast or ovarian cancer. Estimates on penetrances
have been based on retrospective studies and have
arrived at diverging results.
Retrospective reports include the possibility of pre-
senting the selection criteria as results [1]. Some studies
tested one affected proband and calculated on number
of affected close relatives [2,3]. In such studies, preva-
lences of close relatives to be mutation carriers, as well
as age of onset of disease in the relatives, is related to
ascertainment of the proband (age, complete or incom-
plete ascertainment), and the reported results reflect
assumptions on these factors. Others reported findings
based on mutation testing in extended families to avoid
some of these confounders and arrived at higher pene-
trance estimates [4-7]. Reports including prospective
series are limited [8-10].
The suggestion that genetic modifying factors of pene-
trance should underly the conflicting results has not
been confirmed, but the possibility of three modifiers
inferring hazard ratio (HR) of 1.1 to 1.3 in BRCA2
mutation carriers, and one locus with HR 1.1 for
BRCA1 remain. The three loci are outside linkage dis-
tance for both BRCA1 and BRCA2 and will combined
with the HRs reported have marginal impact on total
risk estimates for relatives [11]. Discussing the theoreti-
cal concepts of modifiers of penetrances and expressions
in depth, as well as the pitfalls in examining for such
factors, are outside the scope of this reports.
We have suggested that all incident cases of breast or
ovarian cancer in Norway should be offered testing for
the Norwegian deleterious BRCA1 and BRCA2 muta-
tions. While considering our suggestion, the Norwegian
Government asked for documentation of the pene-
trances of the mutations in question. We decided to
analyze our prospective series to arrive at prospectively,
empirically observed annual incidence rates to answer
the question, and report our findings here. The main
goal was to describe annual incidence rate in those who* Correspondence: moller.pal@gmail.com1Section of Cancer Genetics, The Norwegian Radium Hospital, Oslo
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had had no cancer before inclusion and who had no
cancer demonstrated at first (prevalence) round.
Materials and methods
We have subjected healthy women at risk for breast or
ovarian cancer by family history to prospective follow-
up for two decades. Details on ascertainment methods
have been previously published [12-17]. Genetic testing
was facilitated by the demonstration of Norwegian foun-
der mutations and rapid and cheap tests to demonstrate
them. BRCA founder mutations is not specific for Nor-
way, but the mutations are different in different ethnic
groups [6,18]. Close to all families assumed by family
history to have inherited breast or ovarian cancer have
been tested for at least the 10 most frequent Norwegian
mutations (for review, test panel and geographical distri-
bution of the Norwegian founder mutations, see Møller
et al. [16]).
The families were ascertained according to preset cri-
teria as previously published [7]. We examined at least
one affected per family with sequencing and MLPA, if
available. If no affected was available, we have in many
families sequenced obligate male carriers or young
daughters.
As mentioned above, most BRCA mutations demon-
strated in Norway have passed through the bottleneck
caused by the Bubonic plagues 25 generations ago, and
the population parts have lived separately until a few
generations ago [16]. The consequence is that most
mutations still are located to one single geographical
area, and the families themselves are aware of this and
give a precise description if asked. We have over two
decades classified the families according to both geogra-
phical origin and present address of current members.
Our electronic medical files include zip-codes for all
women either with breast or ovarian cancer or at risk
according to family history, and were used to identify
families for geographical locations. Whenever a muta-
tion not included in the general test panel was
described, the family was extended as far as possible, the
likely geographical origin(s) of the mutation determined,
and all families connected to that area were tested for
that mutation.
We included mutations causing direct stop, frameshift
or large insertions/deletions and splice defects. It is
agreed that such mutations are considered deleterious
(see BIC: http://research.nhgri.nih.gov/bic/). To avoid
discussions on validity of results, we excluded missense
mutations in the finger domains considered deleterious
by some [2], all forms of mutations in the last coding
exon in BRCA2, and all intron variations outside +/-
two bases from the exons considered to be splice donor
or receptor sites. We did, however, include the BRCA
c.1A>G mutation as it is locally frequent in one area
and obviously follows the disease in all families affected
(to be reported separately). A list of the deleterious
mutations included in the present report, is posted on
our web-site http://www.inherited-cancer.com.
Whenever a mutation was found, predictive testing
was offered to the family members pending consent
from the proband to do so. Compliance to predictive
testing has been demonstrated to be high [19]. Most
families are expanded far beyond any selection criteria,
many of them to distant relatives often more than 5
meioses apart from the index person. In one family, a
de-novo BRCA2 c.8090_8115del16 mutation was demon-
strated (both parents without mutation, paternity con-
firmed by DNA testing).
Mutation testing was performed under national legis-
lation including genetic counseling and written informed
consent for each single patient. No named information
was exported from the medical files, no research registry
including patient identifications was erected. The medi-
cal database and application was constructed by Oracle
10 g© and Delphi 2007© and the data for this report
extracted by TOAD© by PM and NC.
All healthy women with a deleterious BRCA1 or
BRCA2 mutation were offered annual follow-up from
age 25 years on, aiming at early diagnosis and treatment.
The same offer was given women with past or present
cancer, if they were assumed to benefit.
The patients have been followed with annual examina-
tions [12-17], and some have opted for risk-reducing
surgery [17,20]. Observation time was calculated as time
between first and last recorded results. All cases of
breast or ovarian cancers in the observation period were
recorded as events irrespective of detection method,
including interval cancers. No other cancer or any other
disease was scored as event. Each woman was counted
once only for having or not having breast or ovarian
cancer prior to inclusion. Each woman was scored once
only for cancer at first examination irrespective of how
many tumours possibly detected. Each woman was
scored once only for having or not having demonstrated
breast or ovarian cancer at follow-up. In theory, one
woman may have been scored for having cancer in all
three groups mentioned, but not more than once in any
group.
All data from the reporting centres including March
2009 are reported. Founder BRCA1 mutation series
from Bergen was incomplete, and all BRCA1 founder
mutation carriers from Bergen were excluded.
Observation time was censored at first demonstrated
breast or ovarian cancer at follow-up. Observation time
was censored at both bilateral risk-reducing mastectomy
and oophorectomy. No correction was done for those
having had only the one or the other risk-reducing
intervention. As previously reported, ovarian cancer may
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have some time in preclinical detectable stage, and we
did diagnose some through risk-reducing oophorectomy
[17]. Censoring the study at that time, might have given
false high penetrance estimates. The way we did it,
implies the risk of arriving at too low penetrance esti-
mates, which we decided to prefer.
Age related annual incidence rates were calculated as
number of women who contracted one or more cancer
divided by numbers of observation years of women hav-
ing the ages at first control as specified in Table 1 and
Table 2.
Confidence intervals of means were considered by
assuming Poisson distributions, groups were compared
two-by-two by Fishers’ exact p.
Results
All together 1055 women were identified as having a
deleterious BRCA1/2 mutation and examined once or
more. At first (prevalence) round, 54 among them were
diagnosed as having breast and/or ovarian cancer, arriv-
ing at a prevalence of 5.1%.
Among these, 870 were examined twice or more.
Through 4830 follow-up years 147 among them were
diagnosed as having breast and/or ovarian cancer, arriv-
ing at an overall annual incidence rate irrespective of
age to be 3.0%.
These 870 were fractionated into three groups: a) the
four BRCA1 founder mutations for which we have pre-
viously reported retrospective cumulative incidence
rates, b) other BRCA1 mutations, and c) BRCA2 muta-
tions. These three groups were split into two groups
each: Those with no cancer prior to inclusion as well as
with no cancer at first control, and those who did have
a cancer prior to inclusion or demonstrated cancer at
first control. The overall annual incidence rates irrespec-
tive of age in those who had no prior or prevalent can-
cer, were 2.7% for BRCA1 founder mutations, 3.6% for
less frequent BRCA1 mutations, and 2.5% for BRCA2
mutations.
Then we fractionated each of the six groups defined
above, into three groups each: those aged 25-39 years at
inclusion, those aged 40-59 years at inclusion, and those
aged 60 years or more at inclusion. The results for
women without a previous cancer and no cancer at pre-
valence round are detailed in Table 1. In the age group
40-59 years at inclusion, annual incidence rates were
4.0% for BRCA1 founder mutations, 5.9% for less fre-
quent BRCA1 mutations, and 3.5% for BRCA2 muta-
tions. For all age groups, the annual incidence rates for
women with founder mutations were less than for
women with less frequent BRCA1 mutations. None of
the differences between the three mutation groups were
statistically significant.
The corresponding details for patients having had
breast or ovarian cancer before inclusion, or at first con-
trol, are given in Table 2.
Discussion
This prospective report confirms the previously reported
penetrance estimates for the four most frequent BRCA1
mutations in Norway. As the healthy mutation carriers
reported here are the next generation in the families
previously reported, the finding was that disease contin-
ued to occur prospectively as previously reported retro-
spectively in these families.
The point estimates for annual incidence rates for the
less frequent BRCA1 mutation carriers were higher than
for those having a BRCA1 founder mutation. This may
Table 1 Results of follow-up: Women without cancer before and at first (prevalence) control.
Mutation group Age group n Observation
years
Cases with prospective cancer Mean observation time Annual incidence rate
B1F <40 195 1282 27 6.6 2.1%
40-59 121 749 30 6.2 4.0%
60+ 19 121 2 6.4 1.7%
SUM 335 2152 59 6.4 2.7%
B1NF <40 119 721 18 6.1 2.5%
40-59 62 320 19 5.2 5.9%
60+ 10 60 3 6.0 5.0%
SUM 191 1101 40 5.8 3.6%
B2 <40 64 347 5 5.4 1.4%
40-59 51 258 9 5.1 3.5%
60+ 8 29 2 3.6 6.9%
SUM 123 634 16 5.2 2.5%
ALL SUM 649 3887 115 6.0 3.0%
B1F: BRCA1 founder mutations (1675delA, 1135insA, 3347delAG, 816delGT)
B1NF: All other BRCA1 mutations
B2: BRCA2 mutations
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be a methodological artifact, as only one third of the less
frequent BRCA1 mutations carried by the prospective
cases, were included in the test panel applied to all
families (data not given in results). However, as
described in methods above we have over years searched
for all the rare mutations in the geographical areas they
are connected to, and have described a number of deli-
neated areas with local founder mutations not present
in the other population parts. The majority of families
carrying rare mutations were not detected through
sequencing a prospectively demonstrated cancer case: In
the files at The Norwegian Radium Hospital which was
available for detailed analysis, 547 women in 127 differ-
ent kindreds were identified to have rare BRCA1 muta-
tions, while the number of prospectively detected
cancers in women with no cancer prior to or at first
control and with rare BRCA1 mutations not included in
the test panel used for all families, was 24. The influence
of a selection error remains, but the probability that the
selection problem had a major effect on the results may
be limited.
An alternative speculation may be that there may have
been an element of selection: The rare mutations may
be rare because they have reduced fitness. If so, previous
reports based on the most frequent mutations may be
underestimates if applied to the less frequent mutations.
If true, this may explain some of the discrepancies in
the literature discussed above. The resources needed to
clarify this, would imply full-scale sequencing in num-
bers which were not available to us and still not is. An
answer may await new technology making sequencing of
large numbers awailable and affordable.
We here report incidence rate as number of cases
affected among the patients exposed during a given
period of time [21], and grouped the patients accord-
ing to age at first examination. As seen in the tables,
the average follow-up period was about 6 years, mean-
ing that the observed annual incidence rates reflected
the risk per year of becoming affected the next 6 years
for healthy women in the given age groups.
Retrospective reports are most often constructed dif-
ferently: they report cumulative incidence rate by age,
starting at birth. We did so in our previous retrospective
reports [4,7]. For comparison with the current results,
we recalculated our previous figures to reflect age
related annual incidences among those who had experi-
enced no cancer before reaching the various age groups.
Doing so, the annual incidence rates in the retrospective
series were 1.0%, 3.0%, 3.5% and 2.5% for the age groups
30-39, 40-49, 50-59 and 60-69 years, respectively (see
Heimdal et al [7], table three, coloumn C for the data
used for calculations). This is close to what we prospec-
tively observed in the present series. The younger group
<40 years in the present series had an average age at
inclusion of 32 years and was followed for an average of
6 years, meaning that the mean age was about 38 years
and the annual incidence rate was expected to be higher
than derived from the retrospective series for the age
group 30-39. The lower annual incidence rate observed
in the older group 60+ years may reflect a diminishing
annual incidence rate in older ages. All variations dis-
cussed here were, however, statistically insignificant and
may have been caused by random variation in small
numbers.
Numbers included with a previous cancer or a cancer
demonstrated at first round, were insufficient to draw a
firm conclusion. The impression was, however, that
those having had a cancer had the same risk for a new
Table 2 Results of follow-up: Women with cancer before or at first (prevalence) control.
Mutation group Age group n Observation
years
Cases with prospective cancer Mean observation time Annual incidence rate
B1F <40 20 78 5 3.9 6.4%
40-59 64 299 7 4.7 2.3%
60+ 16 55 3 3.4 5.5%
SUM 100 432 15 4.3 3.5%
B1NF <40 21 111 2 5.3 1.8%
40-59 38 173 3 4.6 1.7%
60+ 15 42 4 2.8 9.5%
SUM 74 326 9 4.4 2.8%
B2 <40 4 19 2 4.8 10.5%
40-59 28 119 3 4.3 2.5%
60+ 15 47 3 3.1 6.4%
SUM 47 185 8 3.9 4.3%
ALL SUM 221 943 32 4.3 3.4%
B1F: BRCA1 founder mutations (1675delA, 1135insA, 3347delAG, 816delGT)
B1NF: All other BRCA1 mutations
B2: BRCA2 mutations
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primary as those who had not had a previous cancer.
This group was not the goal for the current study, and
we do not discuss this further.
Penetrance observed for BRCA2 mutation carriers
was similar to BRCA1 founder mutations. From the lit-
erature, we had expected lower. Both King et al. 2003
and Antoniou et al 2003 did report increasing pene-
trance of BRCA mutations today compared to previous
generations. Our findings may support their notion. If
this were to be true, it may explain some of the con-
troversies in retrospective studies in different countries
and ethnic groups. This adds to variation in pene-
trances and methodological problems, as discussed
above, to explain controversies between retrospective
reports.
Prospectively observed survival of patients with
BRCA1 mutations and with breast or ovarian cancer, is
50% or less in 10 years [13,15]. It follows that the risk of
dying from breast or ovarian cancer is at least half the
annual incidence rates of contracting cancer reported
here. Prospects for better treatment modalities and pre-
vention strategies are outside the aims of the current
report and are not discussed here.
In conclusion, we have confirmed high penetrances
of BRCA1 and BRCA2 mutations in a prospective ser-
ies. The annual incidence rates presented are empirical
observations which may be used for genetic counseling
of healthy women a with stop, frameshift or large dele-
tion/insertion mutation in the BRCA1 or BRCA2
genes. In the given age groups, our results may be con-
sidered annual risk of breast or ovarian cancer in the
next 6 years to come. In addition, our findings may
give reason to examine further whether or not rare
BRCA1 mutations may be rare because they have
lower fitness than the most frequent BRCA1
mutations.
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